Surgical Resection Versus Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma (BCLC-B): An Unsolved Question.

Détails

ID Serval
serval:BIB_1275C0764544
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Lettre (letter): communication adressée à l'éditeur.
Collection
Publications
Institution
Titre
Surgical Resection Versus Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma (BCLC-B): An Unsolved Question.
Périodique
Hepatology
Auteur(s)
Labgaa I., Demartines N., Melloul E.
ISSN
1527-3350 (Electronic)
ISSN-L
0270-9139
Statut éditorial
Publié
Date de publication
02/2019
Peer-reviewed
Oui
Volume
69
Numéro
2
Pages
923
Langue
anglais
Notes
Publication types: Letter ; Comment
Publication Status: ppublish
Résumé
We have read the article of Hyun MH et al. with great interest (1). We commend the authors for this study that tackles a crucial point in the treatment of hepatocellular carcinoma (HCC). There is a critical need to refine and eventually to expand the selection criteria of HCC patients who may benefit from curative therapies such as surgical resection (SR). There is accumulating evidence on improved survival after SR as opposed to transarterial chemoembolization (TACE) in patients with intermediate stage HCC (Barcelona Clinic Liver Cancer Stage B (BCLC-B)), although American (AASLD) and European (EASL) consensus guidelines recommend TACE in this setting (2, 3). This article is protected by copyright. All rights reserved.
Mots-clé
Carcinoma, Hepatocellular/surgery, Chemoembolization, Therapeutic, Hepatectomy, Humans, Liver Neoplasms/surgery
Pubmed
Web of science
Open Access
Oui
Création de la notice
07/11/2018 12:05
Dernière modification de la notice
26/06/2020 5:21
Données d'usage